Preparation and application of a highly efficient lentiviral vector for knocking down PLXNA1
By constructing shRNA and Lenti-shPLXNA1 lentiviral vectors for PLXNA1, the problem of loss of stemness characteristics in GSCs during in vitro culture was solved, achieving stable culture of GSCs and expression of key factors, supporting related research.
Patent Information
- Application Number
- CN202510627882.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-15
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies struggle to maintain the stemness characteristics of glioma stem cells (GSCs) efficiently in vitro. Under conventional culture conditions, they easily lose their biological representativeness, and the culture models are unstable, making it difficult to simulate the complexity of the in vivo microenvironment.
Using PLXNA1 shRNA and the lentiviral vector Lenti-shPLXNA1, the lentiviral vector Lenti-shPLXNA1 was constructed by knocking down PLXNA1 gene expression to maintain the stemness characteristics of GSCs.
It effectively maintains the stemness of GSCs, enhances their spheroidization ability and the level of the key factor c-Myc protein, provides a more precise in vitro culture strategy, and supports subsequent research on pathological mechanisms and drug targets.
Smart Images

Figure CN123107989A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of genetic engineering, specifically to the preparation and application of a lentiviral vector that efficiently knocks down PLXNA1. Background Technology
[0002] Glioma stem cells (GSCs) are a core driver of glioma malignant progression, significantly influencing tumor recurrence and invasiveness through mechanisms such as self-renewal, heterogeneous differentiation, immune escape, and treatment resistance. GSCs maintain stemness characteristics by utilizing the hypoxic microenvironment (HIF-1α / HIF-2α signaling axis) and perivascular microniches (e.g., the Notch pathway), promoting tumor proliferation and invasion. GSCs can also interact with plasma cells and macrophages in the immune microenvironment, further creating an immunosuppressive environment and accelerating tumor progression. Furthermore, GSCs exhibit particularly strong resistance to radiotherapy and chemotherapy; treatment-induced cellular senescence may trigger stemness reprogramming through HIF1α / HIF2α regulation, leading to the formation of more aggressive cell subsets. Therefore, exploring the functional characteristics of GSCs and developing corresponding targeted therapeutic strategies has significant clinical implications for glioma treatment.
[0003] GSCs rely on a hypoxic microenvironment, physical support from the extracellular matrix, and paracrine signaling from vascular niches in vivo. Due to their unique characteristics, in vitro culture of GSCs presents certain challenges. Under standard culture conditions, GSCs easily lose their stemness characteristics, thus diminishing their research significance.
[0004] During the culture of cytosolic blood cells (GSCs), specific growth factors are typically administered to activate pathways such as HIF and Notch, thereby mimicking the in vivo microenvironment maintained by GSCs. In vitro culture, while adding specific active factors to conventional culture media (such as serum-free media containing EGF / bFGF) can partially maintain stemness, the lack of dynamic oxygen concentration gradients and mechanical stress leads to the gradual loss of stemness marker expression. Furthermore, long-term culture can induce GSCs to differentiate, weakening their biological representativeness. The GSC population contains different functional subpopulations (such as mesenchymal and preneural types), each with varying requirements for growth factors and metabolic substrates. Conventional culture conditions may selectively enrich a particular subpopulation, causing the cell composition in the experimental model to deviate from the original tumor, exacerbating model instability. The GSC population itself is highly heterogeneous, with significant differences in the responses of different subpopulations to culture conditions, and in vitro culture may induce cell fusion, increasing the uncontrollability of the experimental model.
[0005] Currently, to maintain the stemness of cytosolic cells (GSCs), attempts have been made during GSC culture to activate the HIF-1α / HIF-2α signaling pathway using a hypoxic incubator (1%-5% O2) to maintain the stemness characteristics of GSCs and inhibit cell differentiation. However, in vitro models also struggle to replicate the complexity of in vivo hypoxia gradients, extracellular matrix dynamic remodeling, and immune cell infiltration. Furthermore, differences in culture medium composition, hypoxia conditions, or substrate gel types used by different laboratories may make cross-sectional comparisons of research results difficult.
[0006] Therefore, it is necessary to develop more precise and effective GSCs culture strategies to effectively maintain the stemness of GSCs during the culture process, so as to more accurately simulate the tumor microenvironment and analyze the functional heterogeneity of GSCs, thereby breaking through the existing culture bottlenecks. Summary of the Invention
[0007] To address the aforementioned technical problems in the prior art, this invention provides a PLXNA1 knockdown shRNA and lentiviral vector for maintaining the stemness of GSCs, providing technical support for related research.
[0008] The technical solution of this invention is as follows:
[0009] The first objective of this invention is to provide an shRNA of PLXNA1, the nucleotide sequence of which is: 5'-GCAGUACUGACAACGUCAATT-3' (shown in SEQ ID NO.1).
[0010] The second objective of this invention is to provide a lentiviral vector for shPLXNA1, Lenti-shPLXNA1, wherein the shPLXNA1 lentiviral vector is constructed by using the lentiviral vector pLKO.1-Puro as the backbone and introducing the shRNA shown in SEQ ID NO.1 between the restriction enzyme sites Age I and EcoRI.
[0011] A third objective of this invention is to provide the application of the aforementioned PLXNA1 shRNA in maintaining the stemness of glioma stem cells.
[0012] A fourth objective of this invention is to provide the application of the aforementioned lentiviral vector Lenti-shPLXNA1 of shPLXNA1 in maintaining the stemness of glioma stem cells.
[0013] The application described in this invention is to maintain the stemness of glioma stem cells in in vitro culture of glioma stem cells.
[0014] The beneficial effects of this invention are as follows:
[0015] This invention constructs a lentiviral vector with PLXNA1 knockdown and experimentally verifies its effect on GSC stemness, providing an effective way to regulate PLXNA1 expression levels to influence GSC stemness. Maintaining GSC stemness by knocking down PLXNA1 will provide important technical support for GSC cell culture and is of great significance for subsequent research on pathological mechanisms and drug targets. Attached Figure Description
[0016] Figure 1 Lenti-shPLXNA1 atlas.
[0017] Figure 2 The inhibitory effect of Lenti-shPLXNA1 lentiviral vector and control vector on PLXNA1 expression level.
[0018] Figure 3 The effects of Lenti-shPLXNA1 lentiviral vector and control vector on maintaining glioma stem cell stemness-related indicators (spheroidization ability); Figure A shows the number of spheroids directly observed under a microscope, and Figure B shows the statistical data of Figure A.
[0019] Figure 4 The enhancing effects of Lenti-shPLXNA1 lentiviral vector and control vector on c-Myc, a key factor in maintaining the stemness of glioma stem cells; Figure A shows the c-Myc protein level detected by Western blot, and Figure B shows the statistical analysis of Figure A. Detailed Implementation
[0020] The present invention will be further explained below with reference to the embodiments, but the embodiments do not limit the present invention in any way.
[0021] Example 1
[0022] (1) A highly efficient shRNA sequence for knocking down PLXNA1 was designed using the human PLXNA1 gene sequence as a template. Its base sequence is as follows: 5'-GCAGUACUGACAACGUCAATT-3'. At the same time, a control shRNA sequence was designed. Its base sequence is as follows: UUCUCCGAACGUGUCACGUTT (SEQ ID NO.2).
[0023] (2) A method for preparing the lentiviral vector Lenti-shPLXNA1 with high efficiency knockdown of PLXNA1, comprising the following steps: using the lentiviral vector pLKO.1-Puro (purchased from Addgene) as the backbone, introducing the restriction enzyme sites Age I and EcoRI; cloning the sequence into the vector to obtain the Lenti-shPLXNA1 lentiviral vector ( Figure 1 ) and control vector;
[0024] After transfecting HEK293FT cells with this virus and a control virus, RNA was collected, and the knockdown efficiency of PLXNA1 was verified using real-time quantitative PCR. The results showed that Lenti-shPLXNA1 induced a decrease in PLXNA1 expression levels. Figure 2 ).
[0025] (3) Packaging and purification of high-titer Lenti-shPLXNA1 virus: The validated Lenti-shPLXNA1 lentiviral vector was packaged and purified to a viral titer of 4.88 × 10⁻⁶. 8 .
[0026] (4) Effect of Lenti-shPLXNA1 on GSCs: GSC07 and GSC27 glioblastoma stem cells were transfected with Lenti-shPLXNA1, and puromycin was added to select stable transfected cell lines. Lenti-shCon was set up as a control group.
[0027] The experimental results showed that, compared with the control group, the number of cell spheres in the Lenti-shPLXNA1 transfection group was significantly increased. Figure 3 Elevated levels of the key stem cell gene c-Myc protein indicate that Lenti-shPLXNA1 helps maintain its stemness. Figure 4 ).
[0028] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. The shRNA of PLXNA1, characterized in that, The nucleotide sequence of the shRNA is shown in SEQ ID NO.
1.
2. The lentiviral vector Lenti-shPLXNA1 of shPLXNA1, characterized in that, The shPLXNA1 lentiviral vector was constructed by using the lentiviral vector pLKO.1-Puro as the backbone and introducing the shRNA shown in SEQ ID NO.1 between the restriction enzyme sites Age I and EcoRI.
3. The use of PLXNA1 shRNA as described in claim 1 in maintaining the stemness of glioma stem cells.
4. The use of the lentiviral vector Lenti-shPLXNA1 of claim 2 in maintaining the stemness of glioma stem cells.
5. The application according to claim 3 or 4, characterized in that, The application is to maintain the stemness of glioma stem cells in in vitro culture of glioma stem cells.
